Results 11 to 20 of about 12,266 (204)
Virtual Screening of Phytochemicals From Medicinal Plants as Promising PDE5 Inhibitors Against Erectile Dysfunction. [PDF]
Food Sci NutrPhytochemicals from Algerian medicinal plants were virtually screened as potential phosphodiesterase‐5 (PDE5) inhibitors for erectile dysfunction therapy. Drug‐likeness and toxicity analyses identified catechin, ellagic acid, and rosmarinic acid as safe, bioavailable candidates.
Boudou F +7 more
europepmc +2 more sources
The efficacy of PDE5 inhibitors in diabetic patients. [PDF]
Andrology, 2023 AbstractBackgroundPhosphodiesterase 5 inhibitors (PDE5i), since their introduction in the late 1990s, have proven their efficacy in treating several conditions, predominantly pulmonary hypertension and erectile dysfunction where they remain the first‐line therapeutic option.
Swiecicka A.
europepmc +3 more sources
PDE5 inhibitors for LUTS [PDF]
Prostate Cancer and Prostatic Diseases, 2009 To review the current literature regarding the relationship between lower urinary tract symptoms (LUTS) and erectile dysfunction (ED), and the role of phosphodiesterase-5 (PDE5) inhibitors for the treatment of LUTS. Review of recently published (1990-2009) data regarding epidemiologic and pathophysiologic mechanisms are involved in LUTS-ED, focusing on
S, Mouli, K T, McVary
openaire +2 more sources
PDE5 inhibitors beyond erectile dysfunction [PDF]
International Journal of Impotence Research, 2007 The phosphodiesterase type-5 (PDE5) inhibitors sildenafil, vardenafil and tadalafil are widely used first-line therapy for erectile dysfunction (ED). Since the advent of sildenafil in 1998, more than 40 million men worldwide have been successfully treated with these compounds.
P, Sandner +4 more
openaire +2 more sources
Translational Oncology, 2020 Widespread cGMP-specific phosphodiesterase 5 (PDE5) inhibitor use in male reproductive health and particularly in prostate cancer patients following surgery has generated interest in how these drugs affect the ability of residual tumor cells to ...
William Hankey +8 more
doaj +1 more source
Erectile dysfunction - an update of current practice and future strategies [PDF]
, 2013 Erectile dysfunction (ED) is defined as the inability to achieve and maintain a penile erection adequate for satisfactory sexual intercourse.1 Up to 150 million men worldwide suffer from ED and this figure is likely to double by the year 2025.2 A number
Kalsi, J, Muneer, A
core +1 more source
Effect of phosphodiesterase inhibitors in the bladder
Asian Journal of Urology, 2015 Many aging men will experience lower urinary tract symptoms (LUTS). Phosphodiesterase type 5 (PDE5) inhibitors have shown promise in treating LUTS in these patients.
Bilal Chughtai +3 more
doaj +1 more source
Selective inhibition of phosphodiesterases 4, 5 and 9 induces HSP20 phosphorylation and attenuates amyloid beta 1-42 mediated cytotoxicity [PDF]
, 2016 Phosphodiesterase (PDE) inhibitors are currently under evaluation as agents that may facilitate the improvement of cognitive impairment associated with Alzheimer's disease. Our aim was to determine whether inhibitors of PDEs 4,5 and 9 could alleviate the
Baillie, George S. +4 more
core +1 more source
5-Hydroxy-3-(4-hydroxyphenyl)-8,8-dimethyl-6- (3-methylbut-2-enyl)pyrano[2,3-h]chromen-4-one [PDF]
, 2018 Natural and semi-synthetic compounds are being studied as novel phosphodiesterase 5 (PDE5) inhibitors for the treatment of erectile dysfunction, pulmonary hypertension, and lower urinary symptoms.
Ongaro, Alberto +2 more
core +1 more source
Treating erectile dysfunction when PDE5 inhibitors fail [PDF]
BMJ, 2006 New oral drugs, especially phosphodiesterase type 5 (PDE5) inhibitors, have revolutionalised the treatment of erectile dysfunction by decreasing reliance on more invasive options. These inhibitors compete with cyclic GMP (guanosine monophosphate) for the PDE5 receptor site.
Chelsea N, McMahon +2 more
openaire +2 more sources